Ikarovec

Executive Summary

Ikarovec is a UK-based biotechnology company founded in 2020, pioneering next-generation gene therapies for major chronic eye diseases, with a primary focus on age-related macular degeneration (AMD). The company's platform utilizes bi-functional gene therapy constructs designed to provide long-term, single-injection treatments that address the root causes of sight loss, potentially transforming ophthalmic care. While still in early preclinical stages, Ikarovec's strategy targets a large and underserved market, leveraging cutting-edge gene therapy approaches to overcome limitations of current repeat-injection regimens. The company is privately held and has not disclosed funding or valuation details, indicating a need for capital to advance its pipeline. Ikarovec's success hinges on preclinical validation, securing partnerships, and navigating regulatory pathways. Given the early stage, the risk is elevated, but the high unmet need in AMD and the potential for durable therapy offer significant upside.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data in AMD Models30% success
• Q3 2026Series A Funding or Strategic Partnership50% success
• TBDIND-Enabling Studies Initiation20% success